Kornimate/medical-research-clean huggingface dataset:
an automated, tailored information application for medication health literacy

Conditions: Human Immunodeficiency Virus I Infection

Summary: the purpose of this study is to evaluate the acceptability and efficacy of a computer-based tailored information application designed to promote health literacy in persons treated for hiv infection. the study hypothesis is that the application will be acceptable and usable for persons treated for hiv infection, and will improve their levels of adherence to antiretroviral medication treatment.

health literacy is a critically important problem in improving the effectiveness of health care interventions. patient behaviors essential to the successful treatment of hiv infection, such as high levels of medication adherence, may depend on patients understanding how to take medication, how to solve medication-related problems, and how to cope with medication side effects. an approach that has shown promise in promoting behavior change in hiv+ persons is the information-motivation-behavior skills (imb) model. the intervention proposed in this application will implement a health literacy intervention based in part on insights about behavior change drawn from studies of this model. the purpose of the proposed research is to implement this intervention via a computer-based and automated tailored information application. participants will first complete an automated computer-administered self interview (acasi) that will assess medication knowledge, disease knowledge likely to be related to motivation, and problem solving skills. results of this assessment will feed forward to an automated training application that provides individually-tailored training on these topics. this computer-based program will provide training, test understanding, and if necessary reteach and retest. it will also provide printed information for participants to take home to provide ongoing prompts. this study will comprise two phases. in the first, the program will be developed and tested with potential users to assess its usability and detect problems with the wording of materials. in the second phase, participants' health literacy and cognitive status will be evaluated, their adherence to a medication for hiv infection will be assessed using electronic monitoring, and the effects of the program on their adherence will be tested.

Eligibility criteria:
inclusion criteria: * aged 18 years or older * currently treated with at least one medication for hiv infection * no change in target medication anticipated in the next two months * able to participate in the study intervention in english exclusion criteria: * psychiatric or cognitive disorder of severity sufficient to make the potential participant unable to provide informed consent. * not able to participate in the intervention using english.

Keywords: health literacy hiv medication adherence imb model
the effect of local infiltration of tranexamic acid on postoperative blood loss in orthognathic surgery

Conditions: Postoperative Blood Loss in Patient Undergoing Orthognathic Surgery

Summary: the effect of local infiltration of tranexamic acid in orthognathic surgery remains unclear. this study was conducted to evaluate the difference in postoperative blood loss, measured by surgical drain output, following orthognathic surgery. the investigation involved a within-subject comparison, where each side of the mandible received a different local anesthetic solution: one side was infiltrated with a mixture of lidocaine with adrenaline and tranexamic acid, while the other side received lidocaine with adrenaline and normal saline.


Eligibility criteria:
inclusion criteria: * patients aged 18-50 years * undergoing orthognathic surgery (bilateral sagittal split ramus osteotomies (bssro), with or without le fort i maxillary osteotomy) * asa physical status i-ii exclusion criteria: * genioplasty in the operation * history of allergy to tranexamic acid * history of thromboembolic disorders * use of medications affecting blood coagulation (antiplatelet or anticoagulants) within the past 2 weeks * history of cerebrovascular disease * pregnant or breastfeeding women

Keywords: postoperative blood loss orthognathic surgery bilateral sagittal split ramus osteotomies bsso bssro tranexamic acid
nativis voyager for newly diagnosed gbm

Conditions: Glioblastoma Multiforme

Summary: this feasibility study will assess the effects of the nativis voyager therapy in patients newly diagnosed with gbm. the study will enroll and treat up to 32 subjects and will be combined with standard of care radiotherapy and temozolomide.


Eligibility criteria:
inclusion criteria: * there is pathological evidence of gbm using world health organization (who) classification. * subject received maximal debulking surgery. patients may enroll in the study if received gliadel wafers before entering the trial. any additional treatments received prior to enrollment will be considered an exclusion. * subject must have at least one measurable lesion per rano. * subject is at least 18 years of age. * subject has a karnofsky performance scale (kps) ≥ 60. * subject has life expectancy \> 3 months. * subject has adequate organ and marrow function; see note 1. * subject able to start treatment at least 28 days from tumor resection surgery. * subject has provided signed informed consent. exclusion criteria: * subject has progressive disease per rano. if pseudoprogression is suspected, additional imaging studies must be performed to rule out true progression. * evidence of increased intracranial pressure (midline shift \> 5mm, clinically significant papilledema, vomiting and nausea or reduced level of consciousness) * subject is currently being treated with optune. * subject is currently being treated with other investigational agents. * subject has not sufficiently recovered from prior surgery in the opinion of the investigator. * subject has significant co-morbidities at baseline which would prevent radiotherapy and/or temozolomide treatment. * subject has history of hypersensitivity reaction to temozolomide or a history of hypersensitivity to dacarbazine (dtic). * subject has a clinically significant electrolyte abnormality. * subject has an active implantable (e.g., neurostimulator, pacemaker) or other electromagnetic device that is incompatible with mri. subjects with programmable shunt are excluded from the study. * subject has a metal implant, including a stent, in the head or neck that is incompatible with mri. * subject is known to be hiv positive. * subject is pregnant, nursing or intends to become pregnant during the study period. * subject is participating in other potentially confounding investigational research. * subject has any condition that at the discretion of the investigator would preclude participation in the study. * subject is unable or unwilling to comply with the protocol-required follow-up schedule.
a cross-sectional survey to evaluate diabetes management, control, complications, psychosocial aspects of patients with type 2 diabetes in indonesia

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this study is conducted in asia. the aim of this non-interventional study is to evaluate the current status of diabetes management, control, and complications in diabetic subjects in indonesia.


Eligibility criteria:
inclusion criteria: * people with type 2 diabetes mellitus (dm) who are being treated, with any of the non-pharmacological or pharmacological options, at a particular centre for at least 1 year and who have visited the centre within the last 3-6 months * patients willing to sign informed consent form exclusion criteria: * previous participation in this study * unable to comply with protocol requirements * confirmed or suspected pregnancy
use of drug-coated balloon to improve recanalization of a coronary chronic total occlusion after failed angioplasty

Conditions: Chronic Total Occlusion

Summary: observational retrospective registry to compare effectiveness of paclitaxel-coated vs. non coated balloon angioplasty proximal to a chronic total occlussion (cto) after failed revascularization. primary objective is to determine success rate after repeated percutaneous coronary intervention of a cto 3 to 6 months after paclitaxel-coated balloon angioplasty proximal to the persistent lesion.


Eligibility criteria:
inclusion criteria: * failed recanalization of a cto in patients with clinical indication for the percutaneous procedure. * patient willing to participate in the study providing signed informed consent. * j-cto score ≥2. exclusion criteria: - unfeasible recanalization of the cto according to the interventional cardiologists of the center.

Keywords: repeated procedure, angioplasty, paclitaxel, drug-coated balloon
genetic polymorphisms of interleukin-1b and tnf-a and hbv-related hepatocellular carcinoma

Conditions: Hepatitis B; Hepatocellular Carcinoma; Chronic Liver Disease

Summary: by detecting polymorphisms of il-1β and tnf-α,this study aims to find the effects of cytokine gene polymorphisms(and their interaction) on susceptibility and severity of hbv-related hcc.

hepatitis b virus (hbv)infection is the major risk factor for chronic liver disease and hepatocellular carcinoma (hcc). host immunogenetic factors contribute to hbv-associated liver damage and/or carcinogenesis. variant cytokine alleles, including tumor necrosis factor-α(tnf-α)and interleukin-1β(il-1β), might contribute to interindividual difference in inflammatory responses and account for heterogeneous disease outcome of infectious disease. by detecting polymorphisms of il-1β and tnf-α,this study aims to find the effects of cytokine gene polymorphisms(and their interaction) on susceptibility and severity of hbv-related hcc.

Eligibility criteria:
inclusion criteria: * hbsag-positive patients exclusion criteria: * hbsag-negative patients

Keywords: cytokine gene hepatitis b hepatocellular carcinoma chronic liver disease
interactive motor imagery in virtual reality

Conditions: Spinal Cord Injury; Stroke

Summary: this project will build and test the first rehabilitation system employing virtual reality (vr)-based observation, motor imagery and execution to treat lower-limb neuropathic pain and motor dysfunction in participants with an incomplete spinal cord injury or another neurological disorder, eg. stroke: ictus-l (interactive computer-based therapy system for legs). patients using the system will control virtual representations of their legs to engage in entertaining gaming interactions.


Eligibility criteria:
inclusion criteria: * age between 16 and 80 * clinically incomplete spinal cord injury (time since injury: chronic \> 1 year; acute \< 3 months) * asi c or d * neuropathic pain and/or motor deficits * diagnosed neurological disorder, eg. stroke exclusion criteria: * any disease limiting training * epilepsy * major depression or psychosis
interest of the immunoscore® as a post-operative complementary tool for the detection of the risk of recurrence in patients with nonmetastatic colorectal cancer

Conditions: Non Metastatic Colorectal Cancer

Summary: evaluate the patient care recommandation induced by the immunoscore® result


Eligibility criteria:
inclusion criteria: * age between 18 and 80 inclusive; * histologically confirmed colon adenocarcinoma; * having undergone a curative resection of stage i, ii or iii colorectal cancer; * diagnosed t1 / t2 / t3 / t4 and n0 / n1 / n2; * eligible to receive 6 months of adjuvant chemotherapy; * having given free, informed and written consent; * agreeing to the use of a tumor sample for research purposes; * being affiliated to a social security system. exclusion criteria: * pregnant or breastfeeding women * legal incapacity or physical, psychological, social or geographical conditions preventing the patient from signing the consent or completing the study. * history of other solid tumor within 3 years before inclusion, with the exception of in-situ cancer of the cervix and skin cancers (basal or squamous) treated and controlled * person subject to a safeguard measure.
cardio-fistular recirculation in patients with chronic heart failure and preserved left ventricle ejection fraction

Conditions: Chronic Kidney Disease 5D; Heart Failure; Heart Failure NYHA Class I; Heart Failure NYHA Class II

Summary: this is a single-arm cohort study aimed to evaluate change of arteriovenous fistula volume blood flow / cardiac output ratio in patients with chronic heart failure (nyha i-ii classes) and with preserved ejection fraction as a result of a hemodialysis session after a "long" interdialysis interval.


Eligibility criteria:
inclusion criteria: * signed informed consent, * \> 18 years * maintenance ("chronic") hemodialysis, * native arteriovenous fistula, * arteriovenous fistula volume blood flow ≥1 l/min, * arteriovenous fistula volume blood flow / cardiac output ratio \< 0.3, * interdialysis weight gain \<5% of "dry" body weight, * sufficient hemodialysis dose (ekt/v \> 1.2), * chronic heart failure (nyha i-ii classes only), * preserved left ventricular ejection fraction (≥50%), * absence of arrhythmias (except first-degree atrioventricular block block), * absence of heart valve disease (except mitral regurgitation grade i-ii), * absence of intradialysis hypo/hypertension * "long" interdialysis interval (3 days). exclusion criteria: * hypo/hypertension during or after hemodialysis, * arrhythmias (except first-degree atrioventricular block) after hemodialysis.

Keywords: arteriovenous fistula hemodialysis cardiac output heart failure volume blood flow cardio-fistular recirculation cardiopulmonary recirculation ejection fraction
a imma master protocol: a study of ly3361237 in participants with at least moderately active systemic lupus erythematosus

Conditions: Systemic Lupus Erythematosus

Summary: the main purpose of this study is to assess the efficacy and safety of ly3361237 in participants with at least moderately active systemic lupus erythematosus (sle). study will last up to 34 weeks and may include up to 15 visits.


Eligibility criteria:
inclusion criteria: * are diagnosed with sle at least 24 weeks before day 1 of study * have documentation of having a score of 10 or more points on the european league against rheumatism (eular)/american college of rheumatology (acr) 2019 classification criteria for sle * have a sledai-2k score ≥6 at screening (day 1) and clinical systemic lupus erythematosus disease activity index 2000 (sledai-2k) score ≥4 (not including any items related to laboratory values) at randomization (day 2) * must be receiving at least 1 background standard-of-care medication for sle exclusion criteria: * participants are excluded if they have received any of the following medications or therapies within the indicated timeframe prior to the randomization visit (day 2). * are currently receiving oral corticosteroids at doses \>20 mg per day of prednisone (or equivalent) or have adjusted the dosage of corticosteroids within 2 weeks before starting study treatment * have received parenteral corticosteroids within 12 weeks before starting study treatment or are expected to require parenteral corticosteroids during the study * have a current or recent acute, active infection * have had a serious, chronic, recurring conditions of herpes simplex, herpes zoster, recurring cellulitis, chronic osteomyelitis) * have human immunodeficiency virus (hiv) infection, hepatitis b virus (hbv), hepatitis c infection (hcv), active tuberculosis (tb) * have active fibromyalgia or active occurrence of an inflammatory condition that, in the investigator's opinion, would make it difficult to appropriately assess sle activity for the purposes of this study * have experienced a cardiac event within 24 weeks to 12 months prior to screening * have a history of clinically significant or uncontrolled illness that in the opinion of the investigator could put the participant at risk to participate in the study * are, in the judgment of the investigator, actively suicidal and therefore deemed to be at significant risk for suicide * are pregnant or are intending to become pregnant or to breastfeed at any time in the study

Keywords: autoimmune disease btla b and t lymphocyte attenuator immune checkpoint inhibitory checkpoint agonist antibody lupus
clinical decision support to increase use of medications for opioid use disorder

Conditions: Medication Abuse; Harm Reduction; Opioid Use Disorder; Supportive Care

Summary: the objective of this study is to evaluate the impact of clinical decision support (cds) in the form of an alert to identify patients who may be at risk of opioid use disorder (oud) and a clinical care pathway helping providers treating patients with opioid use disorder. the pathway provides health care providers with information and suggestions for screening and treatment of opioid use disorder, including treatment with medications. the 2022 centers for disease control and prevention (cdc) clinical practice guideline for prescribing opioids for pain recommends providers asses for and treat opioid use disorder using approved medications for opioid use disorder (moud). this project will randomize primary care providers at the clinic level to a control arm or intervention arm. the control arm will have access to the clinical care pathway, but will not be reminded to utilize the pathway when treating a patient with opioid use disorder. the intervention arm will receive a reminder nudge about the pathway. buprenorphine (a medication used to treat opioid use disorder) prescribing behavior of providers and outcomes of patients will be examined based on medical records data collected during routine care. the study period will be approximately 18 months.


Eligibility criteria:
inclusion criteria: * primary care encounter and * current opioid prescription (not buprenorphine) and active opioid medications over the last 90 days or * documented as on local pain registry "does the patient fit the criteria to be included on the pain registry?" or * has active problem list diagnosis of long-term (current) use of opiate analgesic or * is taking \>=90 morphine milligram equivalents (mme) per day or * prior positive toxicology screen for illicit drugs or * diagnosis of opioid use disorder exclusion criteria: * active cancer diagnosis in the last 1 year * hospice care/palliative care order * sickle cell disease diagnosis
online field test of an appendicitis decision support tool

Conditions: Appendicitis Acute

Summary: after the recent publication of the coda trial comparing antibiotics and surgery for acute appendicitis, the investigators developed a comprehensive decision support tool. this tool will help patients understand the risks and benefits of each treatment and make a treatment decision. this study is an online randomized field test comparing the decision support tool to a control infographic and assessing it's affect on decisional outcomes, such as decisional conflict.


Eligibility criteria:
inclusion criteria: who live in the united states and who have not previously had appendicitis. * workers on amazons mechanical turk platform with an approval rating of 95% or higher * workers on amazons mechanical turk platform who live in the united states * workers on amazons mechanical turn platform who have not previously had appendicitis exclusion criteria: * employees or relatives of employees of the university of washington

Keywords: decision support decision aid decisional conflict
paediatric rural vs urban trauma

Conditions: Paediatric Trauma

Summary: retrospective cohort study examining paediatric trauma admission over 1 year in a rural hospital vs urban centre

as above. all patient data was anonymised.

Eligibility criteria:
inclusion criteria: * all paediatric trauma in each centre over the above time frame, treated operatively, seen on an acute orthopaedic take exclusion criteria: * adults, non-operative trauma

Keywords: paediatric trauma
cody: a study evaluating the safety and efficacy of qtorin 3.9% sirolimus topical gel for the prevention of basal cell carcinomas (bccs) in patients with gorlin syndrome

Conditions: BCCs in Gorlin Syndrome Patients

Summary: a phase 2b study looks at the safety and efficacy of a treatment that is being investigated for people with certain diseases. this study will be conducted at multiple centers in the united states where participants with gorlin syndrome, also known as basal cell nevus syndrome, will be randomly placed into two groups; one group will receive the active topical gel, the other a topical vehicle gel, also know as placebo. participants will apply this topical product to their face once a day for 6 months. the study will be looking at the number of new bccs that develop on the faces of all the participants during this time.


Eligibility criteria:
key inclusion criteria: * adults, 18 years or older * meet diagnostic criteria for gorlin syndrome * willing to avoid application of a non-study topical medication to the face (prescription or over the counter) during the study. * willing to forego treatment of bccs with anything other than the study medication except when the investigator believes that delay of treatment of a bcc potentially might compromise the health of the subject. during the trial, the only allowed form of bcc treatment is surgical. * participant will be encouraged to use their preferred sunscreen with a sun protector factor (spf) of at least 30 daily key exclusion criteria: * recently participated in a clinical trial evaluating an investigational product for the treatment of bccs or gorlin syndrome within 3 months prior to to starting study medication. participant can start the study screening period prior to completing the 3 month washout. * recently used topical or systemic (oral) treatment that might interfere with the evaluation of the study medication.

Keywords: gorlin syndrome basal cell carcinoma nevoid basal cell carcinoma syndrome basal cell nevus syndrome bcns gorlin syndrome alliance prevention topical sirolimus
causes of mortality in kidney transplant recipients

Conditions: Renal Disease

Summary: the causes of mortality in kidney transplant patients and the risk factors for mortality have been widely published. however, there is a high variability according to geographical areas and time. recent studies suggest that the classical hierarchy of causes of mortality, i.e. the predominance of cardiovascular causes of death, could be overturned by the increase in infectious and cancer-related deaths. investigators will try to highlight this paradigm shift and the related risk factors by studying two large french transplantation databases.


Eligibility criteria:
inclusion criteria: * adult subject (≥18 years old) during transplantation * transplantation performed between 01/01/2008 and 31/12/2014 * kidney transplant subject, double transplants kidney + pancreas, or kidney + islets of langherans * subject previously transplanted other organs * subject not objecting, after being informed, to the reuse of their data for the purposes of this research exclusion criteria: * subject who expressed their opposition to participating in the study * subject having received a double transplant during the same operation: kidney + heart, kidney + liver, kidney + lungs

Keywords: renal disease kidney transplant